重组人血小板生成素对比艾曲泊帕治疗中国成人免疫性血小板减少症的多中心双盲双模拟随机研究
该多中心双盲双模拟随机研究纳入96例病程≥6个月、基线血小板<30×10^9/L的中国成人ITP患者,按1:1随机接受艾曲泊帕25 mg/日或rhTPO 300 u/kg治疗2周。第15天rhTPO组达到血小板≥50×10^9/L的比例及完全反应率均显著高于艾曲泊帕组,但停药后rhTPO组血小板1周内降至基线,艾曲泊帕组为第4周。两组不良事件相似。
要点
- 停药后rhTPO组血小板1周内降至基线,艾曲泊帕组为第4周。
核心结论
- rhTPO在快速提升ITP患者血小板计数方面优于艾曲泊帕25 mg/日。
研究设计与样本
- 多中心双盲双模拟随机对照研究,纳入96例病程≥6个月、基线血小板<30×10^9/L的中国成人ITP患者,按1:1随机分组。
主要发现
- 第9、12、15天分析时,rhTPO组更高比例患者血小板快速增至基线2倍且≥30×10^9/L,或至少一次达到≥50×10^9/L。
- 停药后rhTPO组血小板1周内降至基线,艾曲泊帕组第4周降至基线。
- 两组不良事件相似。
临床怎么用
- 对于需快速提升血小板的中国成人ITP患者,可优先考虑rhTPO 300 u/kg治疗2周。
- 需注意rhTPO停药后血小板下降较快,应规划后续维持治疗。
局限性
- 样本量96例,研究周期2周,未报告长期疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We performed a double-blind, double-dummy controlled study to compare the efficacy between recombinant human thrombopoietin (rhTPO) and eltrombopag in rapidly increasing the platelet counts in Chinese patients with immune thrombocytopenia (ITP). A total of 96 patients diagnosed with ITP for ≥6 months who had baseline platelet counts of <30 × 109 /l were randomly assigned (1:1 ratio) to receive eltrombopag 25 mg/day or rhTPO 300 u/kg for 2 weeks. Compared with the eltrombopag group, a significantly higher proportion of patients in the rhTPO group achieved platelet counts of ≥50 × 109 /l [75·00% (36/48) vs. 43·75% (21/48), P = 0·003] or complete response (64·58% vs. 25·00%) on day 15. Moreover, a higher proportion of patients in the rhTPO group either had platelet counts that rapidly increased to twice that of baseline and with platelet counts of ≥30 × 109 /l, or reached ≥50 × 109 /l at least once when analysed on day 9, 12, and 15. However, upon discontinuation of the treatment, the platelet counts reduced to the baseline within 1 week in the rhTPO group, but on the fourth week in the eltrombopag group. Adverse events were similar in patients given rhTPO and eltrombopag. To conclude, rhTPO is superior to eltrombopag at 25 mg/day in rapidly increasing platelet counts in patients with ITP (ClinicalTrials.gov Identifier: NCT03771378).
引用
- Mei H, Xu M, Yuan G, et al. A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients. Br J Haematol. 2021. PMID: 34528239. doi:10.1111/bjh.17808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。